Your session is about to expire
← Back to Search
Lamivudine + Chemoimmunotherapy for Small Cell Lung Cancer
Study Summary
This trial is studying the effect of lamivudine, in combination with standard chemoimmunotherapy, on treating patients with small cell lung cancer that has spread to other parts of the body.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 3 trial • 3526 Patients • NCT00074581Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a condition that weakens my immune system, such as HIV/AIDS.I haven't had a heart attack or blood clot in the last 6 months, and I don't have severe heart disease.I have not had an autoimmune disorder requiring immunosuppressants in the last 2 years.Your liver enzymes (ALT and AST) are not more than 3 times the upper limit of normal. If you have cancer that has spread to your liver, it's okay if your liver enzymes are not more than 5 times the upper limit of normal.I have had only one round of platinum-based chemotherapy for small cell lung cancer.I do not have any serious infections or uncontrolled conditions, including hepatitis.My lung cancer diagnosis was confirmed through lab tests.My cancer has spread to the lining of my brain and spinal cord.My cancer has spread beyond my lungs.I have small cell lung cancer and have had only one round of chemotherapy or chemoimmunotherapy.I have irregular heartbeats that are not well-managed.I have brain metastasis causing symptoms.I have had severe heart failure in the last 6 months.I haven't had major surgery or still recovering from one in the last 2 weeks.Your blood platelet count is at least 100 billion per liter.I can carry out all my self-care but cannot work.I am 18 years old or older.Your absolute neutrophil count is at least 1.5 billion per liter.My kidney function tests are within normal range.Your hemoglobin level is at least 9 grams per deciliter.I haven't had chemotherapy or chemoimmunotherapy in the last 4 weeks, except for allowed treatments.My last treatment with platinum was over a year ago and my small cell lung cancer did not worsen during that treatment.My cancer can be measured and tracked using specific criteria.Your bilirubin levels in your blood need to be within a certain range, unless you have a documented condition called Gilbert's syndrome, in which case slightly higher levels may be acceptable.
- Group 1: Treatment (lamivudine, chemoimmunotherapy)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In what circumstances is Lamivudine usually recommended?
"Lamivudine is often prescribed to treat recurrent, as well as advance directives, advanced cervical cancer, and gestational trophoblastic disease."
Are there unfilled slots available for prospective participants in this experiment?
"According to the clinicaltrials.gov webpage, this medical trial is still searching for participants; it was initiated on July 2nd 2021 with its most recent update being October 20th 2022."
What earlier studies utilized Lamivudine as a therapeutic agent?
"Presently, Lamivudine is the subject of 1209 clinical studies with 332 trials in Phase 3. An abundance of research sites are exploring this medication, from Shanghai to 68270 other locations across the world."
What is the danger-profile of Lamivudine treatments?
"Our team at Power has evaluated Lamivudine's safety as a 2 on their rating system. This judgement is based off the evidence presented in Phase 2 trials, which have offered some insight into its security but no confirmation of efficacy."
How many participants are being recruited for this trial?
"Affirmative. Clinicaltrials.gov indicates that this medical investigation is recruiting now and was initially posted on July 2nd 2021 with the most recent update occuring October 20th 2022. The trial requires 28 test subjects to be sourced from 1 healthcare facility."
Share this study with friends
Copy Link
Messenger